G-CVP therapy using obinutuzumab for follicular lymphoma

Rituximab (R)-combined chemotherapy has improved outcomes in patients (pts) with follicular lymphoma (FL). In addition, obinutuzumab (G) has been approved for FL. R-cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP), R-bendamustine (B), G-CHOP, and GB have often chosen as treatment for FL in clinical practice. For frail or elderly pts, R-CVP excluding doxorubicin has also used. We here report an efficacy and toxicity of G-CVP for frail or elderly indolent FL (grade 1, 2) pts.